Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > still no substance and one hot regulatory stinker
View:
Post by Utopianstocks on Dec 18, 2020 11:37am

still no substance and one hot regulatory stinker

keep popping in and out of this one and this just smells like a massive regulatory stinker.  essentially self promoting vapours with no substance. 

hooray we completed toxicology testing and we referenced the list from guidelines of normal studies it takes. no mention of starting dose, safety, target organ, how long the effects lasted and all the wonderful things real healthcare analysts can get their teeth into.  

BTW FDA always agrees with your planning because its just that planning unlesss you are on a suicide mission that will harm people then they step up.  also, 505b2 is nothing special. lots of folks following this road with synthetic cannabis.   while we are at it the sales and marketing projections are highly suspect especially since you are making assumptions that are best best best case scenario. but if you're a wannabe biotech from la belle province you can be a big fish in a small pond and talk a great game.  

time to pick another asset from your pipeline the shareholders financed and flip it into another shadow company......  

can somebody tell the CEO his only game is regulatory affairs and weekly PRs that have zero substance.  how about a view of the financing, costs, burn rates you know all the fun stuff real drug development actually cares about.  

while you're at it, tell KINGOFSTOCKS his-her promotional messages are landing way short.  he-she is always promoting this dog with fleas by bashing shorts when facts are what really matter.  

love the show though it is quite entertaining.
Comment by Realnewsalways1 on Dec 18, 2020 11:51am
NO....FDA does not always agree to a 505b.2. There are critieria to be met Right from the start you are off and shows your lack of knowledge in the process. Nothing special, are you kidding me...It saves millions of dollars, it saves years to get it approved and offers exclusivity to the drug, other than that you are right Nothing Special......................... Another point shows you have ...more  
Comment by Kingofstockst on Dec 18, 2020 12:25pm
Hey clown I never once promoted or pumped, I've only said listen to the science and the data which there's plenty plenty to read and disect, I always say block the noise ie.. ppl like you lol... I got in at there prices you probably got in over $1 that's not my fault. Anyways glta
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities